93 related articles for article (PubMed ID: 7214295)
21. Phase II evaluation of maytansine in patients with metastatic lung cancer.
Eagan RT; Creagan ET; Ingle JN; Frytak S; Rubin J
Cancer Treat Rep; 1978 Oct; 62(10):1577-9. PubMed ID: 709559
[No Abstract] [Full Text] [Related]
22. Cell cycle phase-specific cytotoxicity of the antitumor agent maytansine.
Rao PN; Freireich EJ; Smith ML; Loo TL
Cancer Res; 1979 Aug; 39(8):3152-5. PubMed ID: 455300
[TBL] [Abstract][Full Text] [Related]
23. Phase II evaluation of maytansine in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group study.
Ratanatharathorn V; Gad-el-Mawla N; Wilson HE; Bonnet JD; Rivkin SE; Mass R
Cancer Treat Rep; 1982 Jul; 66(7):1687-8. PubMed ID: 7093975
[No Abstract] [Full Text] [Related]
24. Acute toxicity of maytansine in F344 rats.
Mugera GM; Ward JM
Cancer Treat Rep; 1977 Oct; 61(7):1333-8. PubMed ID: 563288
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study.
Rosenthal S; Harris DT; Horton J; Glick JH
Cancer Treat Rep; 1980; 64(10-11):1115-7. PubMed ID: 7459897
[TBL] [Abstract][Full Text] [Related]
26. Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors.
Takasugi BJ; Robertone AB; Salmon SE; Jones SE; Alberts DS
Invest New Drugs; 1984; 2(4):387-90. PubMed ID: 6096287
[TBL] [Abstract][Full Text] [Related]
27. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
28. Phase I evaluation of AT-125 single dose every three weeks.
Taylor S; Belt RJ; Joseph U; Haas CD; Hoogstraten B
Invest New Drugs; 1984; 2(3):311-4. PubMed ID: 6511237
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
[TBL] [Abstract][Full Text] [Related]
30. Maytansine.
Issell BF; Crooke ST
Cancer Treat Rev; 1978 Dec; 5(4):199-207. PubMed ID: 367597
[No Abstract] [Full Text] [Related]
31. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Ribrag V; Dupuis J; Tilly H; Morschhauser F; Laine F; Houot R; Haioun C; Copie C; Varga A; Lambert J; Hatteville L; Ziti-Ljajic S; Caron A; Payrard S; Coiffier B
Clin Cancer Res; 2014 Jan; 20(1):213-20. PubMed ID: 24132920
[TBL] [Abstract][Full Text] [Related]
32. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of bruceantin.
Garnick MB; Blum RH; Canellos GP; Mayer RJ; Parker L; Skarin AT; Li FP; Henderson IC; Frei E
Cancer Treat Rep; 1979; 63(11-12):1929-32. PubMed ID: 526926
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of anguidine administered weekly.
Belt RJ; Haas CD; Joseph U; Goodwin W; Moore D; Hoogstraten B
Cancer Treat Rep; 1979; 63(11-12):1993-5. PubMed ID: 526932
[TBL] [Abstract][Full Text] [Related]
36. Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule.
Casper ES; Gralla RJ; Young CW
Cancer Res; 1981 Jun; 41(6):2417-20. PubMed ID: 6940656
[TBL] [Abstract][Full Text] [Related]
37. Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study.
Thompson DS; Hainsworth JD; Hande KR; Holzmer M; Greco FA
Cancer; 1994 Jun; 73(11):2824-31. PubMed ID: 8194024
[TBL] [Abstract][Full Text] [Related]
38. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
[TBL] [Abstract][Full Text] [Related]
39. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
40. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
